Manipulación política y conflicto interno. La presencia insurgente en la zona Mixe Baja de Oaxaca, México, 1812-1818

This article analyzes the behaviour of three mixe villages from Nexapa and Villa Alta subdelegations (Mazatlán, Acatlán y Candayoc) in the face of the insurgent occupation of Oaxaca’s city at the end of 1812. Given that it doesn’t exist studies about this period in the mixe region, this work is a first approach to know the indigenous villages response in this area of Oaxaca, both local and regional level, opposite the political juncture that brought the establishment of an insurgent govern in the Oaxaca’s intendancy between 1812 and 1814.Este artículo analiza el comportamiento de tres pueblos mixes de las subdelegaciones de Nexapa y de Villa Alta (Mazatlán, Acatlán y Candayoc) ante la ocupación insurgente de la ciudad de Oaxaca a finales de 1812. Dada la carencia de estudios sobre este periodo en la región mixe, este trabajo es una primera aproximación para conocer la respuesta de los pueblos indígenas de esta área de Oaxaca, tanto a nivel local como regional, frente a la coyuntura política que significó el establecimiento de un gobierno insurgente entre 1812 y 1814 en la intendencia de Oaxaca

Antiangiogenic therapy for breast cancer

Angiogenesis is an important component of cancer growth, invasion and metastasis. Therefore, inhibition of angiogenesis is an attractive strategy for treatment of cancer. We describe existing clinical trials of antiangiogenic agents and the challenges facing the clinical development and optimal use of these agents for the treatment of breast cancer. Currently, the most promising approach has been the use of bevacizumab, a humanized monoclonal antibody directed against the most potent pro-angiogenic factor, vascular endothelial growth factor (VEGF). Small molecular inhibitors of VEGF tyrosine kinase activity, such as sorafenib, appear promising. While, the role of sunitinib and inhibitors of mammalian target of rapamycin (mTOR) in breast cancer has to be defined. Several unanswered questions remain, such as choice of drug(s), optimal duration of therapy and patient selection criteria

A Multiscale Model Evaluates Screening for Neoplasia in Barrett's Esophagus

National Cancer Institute grants U01 CA152926 (CISNET) (to EGL, JJ, and WDH) and U01 CA182940 (BG-U01) (to EGL and WDH). National Science Foundation (www.nsf.gov) under grant no. DGE-0718124 (to KC